Clinical Trial Update: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 study of talimogene laherparepvec (T-VEC) in combination with pembrolizumab in metastatic and/or locally advanced sarcoma reports results as of 2025; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Angiosarcoma
• Epithelioid Sarcoma
• Sarcoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• T-VEC (talimogene laherparepvec)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Epithelioid Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-29